The market for early diagnosis kits for Alzheimer’s disease is projected to grow substantially by 2031, driven by rising awareness, increased R&D investments, and advancements in biotechnology. Key players in this market include QuantaMatrix, MIND and Tech, Immuno-Biological Laboratories, and PeopleBio. These companies are expanding their product lines and focusing on innovations that enable earlier and more accurate detection of Alzheimer’s biomarkers, such as beta-amyloid and tau proteins.
The market is segmented by type (e.g., blood-based, imaging, genetic testing) and application (hospital, diagnostic laboratories, and research institutions). Regional growth trends show significant expansion in North America and Europe, with Asia-Pacific expected to experience the highest growth rates due to increased healthcare access and government support for Alzheimer’s research​